News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CELLECTIS SA And BASF Plant Science L.L.C. Broaden Their Collaboration To Use Engineered Meganucleases In Crops



3/5/2010 12:49:20 PM

Paris, March 4, 2010 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced that BASF Plant Science has just broadened its license to use Cellectis’ meganuclease technology. BASF Plant Science is the plant biotechnology business of one of the world’s leading chemical company, BASF, and specializes in the research, development and commercialization of transgenic crops.

This agreement extends the license signed by Cellectis and BASF Plant Sciences in January 2006. Under a non-exclusive license, BASF Plant Science will use meganucleases engineered by Cellectis to make targeted modifications of plant genomes.

Financial terms and conditions of the agreement were not disclosed.

“The broadening of an agreement with a high-profile company that has been using our tools and technology for three years is very good news,” said André Choulika, Cellectis CEO. “It confirms that major players in the global agricultural biotechnology field have a high level of confidence that Cellectis’ meganuclease technology has an unparalleled ability to develop the next generation of high added value crops.”

To find out more about BASF Plant Science, please see the web site at: http://www.basf.com/biotechnology.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over €70 million in funding since inception.

More information at www.cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES